Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 98 for “"Acquired resistance"”.
-
Understanding Acquired Resistance to Lapatinib In Breast Cancer Cells
… for clinical use, though patients have developed resistance to the drug, as seen previously with other EGFR inhibitors. Moreover, the therapeutic efficacy varies significantly within the patient population, and the mechanism of drug sensitivity is not fully understood. Expression levels of ErbB2 …
-
Tumor Immunotherapy: Mechanisms of Acquired Resistance and Characterization of Immune Related to xicities
… molecular mechanisms underlying immunotherapy resistance. Through multiple in vivo passages, we selected a B16 melanoma tumor line that evolved complete resistance to combination blockade of CTLA-4, PD-1, and PD-L1, which cures ~80% of mice bearing the parental tumor. Using gene expression …
-
Role of SABP2 in Systemic Acquired Resistance Induced by Acibenzolar-S-Methyl in Plants.
… available chemical inducer of local and systemic resistance (SAR) response in plants. ASM functioning at molecular level is mostly unclear. This research was designed to investigate the mechanism of ASM action in plants. It was hypothesized that SABP2, a plant protein, plays an important role in …
-
Identification of novel determinants of primary and acquired resistance to EGFR-targeted therapies in colorectal cancer
… of these targeted therapies is the existence of resistance, rendering these treatments ineffective. Resistance towards targeted therapies can exist innately within the tumour or can develop over a period of time following prolonged exposure to the targeted therapy. The EGFR-targeted therapy …
-
Role of C-Met and Egfr In Acquired Resistance to Parp Inhibitors In Triple-Negative Breast Cancer
… is modest, suggesting the emergence of resistance. We previously demonstrated that c-MET contributes to intrinsic resistance to PARP inhibitors in triple-negative breast cancer. However, whether c-MET plays a role in acquired resistance to PARP inhibitors in triple-negative breast cancer …
-
The Molecular Consequences of CK2-mediated Phosphorylation of the TGA2 Transcription Factor within Systemic Acquired Resistance of Arabidopsis thaliana
… the pathogen and in more distal tissue. Systemic acquired resistance (SAR) is a type of systemic defence response deployed against biotrophic pathogens resulting in altered plant gene expression and production of antimicrobial compounds. One such gene involved in plant defence is called …
-
Overcoming Acquired Resistance to BRAF Inhibitors by Novel Synergistic Drug Combination and Discovery of Novel Smac Mimetics as Selective Survivin Inhibitors
… a novel combination study of melanoma therapy. Acquired clinical resistance to vemurafenib, a selective BRAFV600E inhibitor, arises frequently after short term chemotherapy. Since the inhibitions of targets in the RAFMEK-ERK pathway result in G0/G1 cell cycle arrest, vemurafenib-resistant cancer …
-
Uncovering Molecular Targets to Overcome Immunosuppression In Non-Small Cell Lung Cancer With Acquired Tki Resistance
… and many other cancers. Unfortunately, however, resistance to such targeted therapies inevitably arise in most patients and can occur through a variety of resistance mechanisms including genomic alterations and upregulation of bypass pathways. Additionally, patients who have acquired resistance …
-
Interrogating therapeutic resistance to oncogenic KRASG12C-based therapies in colorectal cancer
… the clinic. However, treatment-associated resistance mechanisms have long threatened to attenuate clinical benefit through either adaptive or acquired resistance. To better understand the impact of this mutation on this patient population, this dissertation has sought to characterize the …
-
Targeting Autophagy to Improve Efficacy of Cdk4/6 Inhibition In Breast Cancer
… to identify responsive patients and iii) acquired resistance to CDK4/6 inhibitors. Previous <em>in vitro</em> studies have shown that palbociclib mediated CDK4/6 inhibition induces G1 arrest and senescence in ER+ breast cancer cells, and a recent study in fibroblasts implicated a role for …
-
Genomic Evolution of Chemoresistance In Triple-Negative Breast Cancer Delineated By Single Cell Sequencing
… heterogeneity and frequently (46%) develops resistance to neoadjuvant chemotherapy (NAC). Currently, the genomic basis of chemoresistance remains poorly understood. An important question is whether resistance to chemotherapy is driven by the selection of rare pre-existing subclones with …
-
Measuring Single Cell Responses to Lapatinib In A Heterogeneous Population
… a major challenge with targeted therapy is the acquired resistance in the cancer cells to these therapies, quite often very rapidly in the course of a few months. One of the major targets in cancer has been the EGFR/ErbB2 network in breast and other cancer types. Prior work from our lab and …
-
Role of Macrophages In Adaptive Resistance to Anti-Vegf Therapy
… the VEGF pathway in cancer has been limited by acquired resistance; yet, the mechanisms by which this occurs is unclear. We investigated the role of macrophages in the development of acquired resistance to anti-VEGF antibody (AVA) therapy.</p> <p>Materials and Methods: We first established a …
-
Functional Interrogation Of Anti-Cancer Drug Resistance
… to resist upfront target inhibition (intrinsic resistance) as well as, in cases where tumors are initially sensitive, develop resistance over the course of drug treatment (acquired resistance). The literature to date reveals a problem as complex as the tumor itself; the heterogeneity of cancer …
-
Resistance to HER2-targeted therapies in HER2-positive breast cancer
… this, patients often present with de novo resistance, or will develop acquired resistance to targeted therapies. Several resistance mechanisms have been identified but attempts to target them have failed. Thus, it is of paramount importance to identify the mechanisms used, to prevent …
-
Exploiting tumour cell dependency on pro-survival BCL2 proteins with BH3 mimetics
… patient outcomes. However, the development of acquired resistance to these agents is inevitable, highlighting the need for strategies to enhance their primary efficacy in the clinic. Inhibition of ERK1/2 signalling increases the abundance of pro-apoptotic BH3-only proteins such as BIM and BMF. …
-
TGA2 dual activity: N-terminus regulation of reversible DNA binding influenced by NPRI and CK2
TGA2 is a dual-function Systemic Acquired Resistance (SAR) transcription factor involved in the activation and repression of pathogenesis-related (PR) genes. Recent studies have shown that TGA2 is able to switch from a basal repressor to activator, likely, through regulatory control from its …
Page 1 of 5